Aquestive Therapeutics Inc Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event Transcript
(technical difficulty) opportunities and progress relating to our epinephrine program. Before we start, let me make the obligatory statement that during the presentation, the company will be making forward-looking statements. We direct you to the risks and uncertainties affecting the company as described in the forward-looking statement page at the beginning of the PowerPoint presentation being shared with you all today.
I'll turn the program over to the team you really want to hear from in a moment. But first, though, I'd like to take a minute to update everyone on the progress we're making in one of the other key programs at Aquestive, Libervant. As many of you know from our recent earnings call, the company's lead asset is Libervant buccal film. The work we need to do to prepare our NDA resubmission, inclusive of the agency's comments that we recently received is progressing as expected, and we remain on track for a near-term submission of this product with the FDA by the end of the second quarter. We're committed
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |